Atlas Trials

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06581640 · RECRUITING

Trial details

NCT number
NCT06581640
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple MyelomaRelapsed/Refractory
Start date
2024-09-24
Primary completion
2028-12-31
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.